期刊文献+

替考拉宁的药物利用评价 被引量:4

Drug utilization review of teicoplanin
原文传递
导出
摘要 目的:分析我院替考拉宁的使用情况,为临床合理用药提供依据。方法:收集我院住院患者中使用替考拉宁病例45份,填写调查表,并对结果进行统计分析。结果:45例用药中合理与基本合理用药占的48.9%,不合理用药占51.1%。结论:替考拉宁在国内临床应用时间较短,用药不合理的现象较严重,有必要加强替考拉宁合理用药的研究与指导。 OBJECTIVE To analyze the utilization of teicoplanin in our hospital to provide basis for rational use. METHODS Cases of using teicoplanin in our hospital, were collected, analysis of the statistical results was conducted by the questionnaires. RESULTS Of all the 45 cases, the rate of rational and basic rational using teicoplanin was 48. 9%, and the rate of nonrational using teicoplanin was 51.1 %. CONCLUSION In domestic medical cure,teicoplanin has been used in clinical application just for a short period. The irrational utilization of drug is serious, so it's necessary to enhance the research and guidance of rational utilization of teicoplanin.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2009年第22期1934-1936,共3页 Chinese Journal of Hospital Pharmacy
关键词 替考拉宁 药物利用评价 合理用药 teicoplanim drug utilization reviewl rational use of drug
  • 相关文献

参考文献6

二级参考文献30

  • 1陆红,张朴,李家泰.抗生素89-07与庆大霉素动物体内药代动力学比较研究[J].中国抗生素杂志,1995,20(6):434-438. 被引量:22
  • 2Biedenbach DJ, Bell JM, Sader HS,et al. Antimicrobial susceptibility of Gram - positive bacterial isolates from the Asia - Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: A sentry program report (2003 -2004) [J]. Int J Antimicrob Agents ,2007 ;30 : 143 - 149.
  • 3Deshpande LM, Fritsche TR, Moet GJ, et al . Antimicrobial resistance and molecular epidemiology of vancomycin - resistant enterococci from North America and Europe: A report from the sentry antimicrobial surveillance program[ J]. Diagn Microbiol Infect Dis ,2007 ;58:163 - 170.
  • 4Shea KW, Cunha BA. Teicoplanin[ J]. Med Clin North Am, 1995 ;79 : 833 - 844.
  • 5Falcoz C, Ferry N, Pozet N, et al . Pharmacokinetics of teicoplanin in renal failure[ J ]. Antimicrob Agents Chemother, 1987 ;31 : 1255 - 1262.
  • 6Guay DRP, Awni WM, Halstenson CE,et al. Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing [ J ]. Antimicrob Agents Chemother, 1989; 33:2012-2015.
  • 7Bonati M, Traina GL, Rosina R,et al. Pharmacokinetics of a single intravenous dose of teicoplanin in subjects with various degrees of renal impairment[ J ]. J Antimicrob Chemother, 1988;21 ( Suppl. A ) : S29 -S37.
  • 8Traina GL, Gentile MG, Fellin G,et al. Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis [ J ]. Eur J Clin Pharmacol,1986;31:501 - 504.
  • 9Brouard R J, Kapusnik JE, Gambertoglio JG, et al . Teicoplanin pharmacokinetics and bioavailability during peritoneal dialysis [ J ]. Clin Pharmacol Ther, 1989;45:674 - 681.
  • 10Hoffler D, Koeppe P, Naumann E ,et al. Pharmaeokinetics of teieoplanin in hemodialysis patients [ J ]. Infection, 1991 ; 19 : 324 - 327.

共引文献38

同被引文献32

引证文献4

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部